- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02144103
Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Effectiveness and Safety of Subtenon Administration of Autologous Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Fat tissue obtainment:
Subjects will undergo liposuction under local anesthesia. In this procedure, Ringer's solution with the anesthetic lidocaine and vasoconstrictor adrenaline infused into the adipose compartment to minimize blood loss and contamination of the tissue by peripheral blood cells. 15 minutes later a hollow blunt-tipped 3 mm cannula introduced into the subcutaneous space through small (0.5 cm) incision. The cannula attached to syringe and under gentle suction moved through the adipose compartment, mechanically disrupting the fat tissue. Aspirate volume - approximately 150-200 cc. Procedure time - 30 minutes.
ADRC isolation:
Aspirated fat tissue placed into sterile vessel which inserted into Celution 800/CRS System (Cytori Therapeutics Inc) - closed system for automated and standardized extraction and concentration of ADRC. Celution 800/CRS System drains excess of fluid from fat tissue and estimate it's volume After that lipoaspirate washed extensively with equal volumes of Ringer's solution to remove blood. At the end of this process System indicates required volume of enzyme reagent (Celase®) which should be added immediately by operator. After enzyme treatment Celution 800/CRS System automatically transfers isolated ADRC into washing compartment where ADRC washed and concentrated in 5 mL suspension. Tissue processing time - approximately 60 minutes. ADRC suspension match all requirements listed in technical documentation for Celution 800/CRS System. Obtained ADRC divided into 2 portions. First portion (0.2-0.5 mL) used for counting, viability and sterility assessment. Second portion placed into sterile syringe for injection.
Subtenon injection of ADRC:
Antiseptic and anesthetic solutions instilled into conjunctival sac. After that blepharostat installed. The patient is asked to look in opposite to the injection side direction. Doctor inserts a needle into inferior temporal quadrant between rectus muscles,10-12 mm from the limbus. Needle should be moved slowly, as close as possible to the eyeball. After needle placement at the depth of 5-7 mm doctor injects concentrated solution of ADRC (up to 0,5 ml per single injection). Injection is made by insulin syringe with a needle size 0.45 mm * 12mm (26 G).
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Moscow, Russian Federation, 121359
- Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies
-
Moscow, Russian Federation, 119002
- Federal State Budgetary Institution "Outpatient Health Center №1" of the Business Administration for the President of the Russian Federation
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient suffers from primary open-angle glaucoma (II and III stages; singe eye or both eyes) at least for 6 months
- Intraocular pressure is stable for at least for 3 months
- Visual acuity of each eye (measured by using visual acuity charts projector) not less than 0,1
- Patient is familiar with Participant information sheet
- Patient signed informed consent form
Non-inclusion Criteria:
- Contraindications to the local anesthesia or medical history of allergic reactions to local anesthetics
- Any anomalies or conditions of at least one eye which can limit tonometry implementation
- Inflammatory disease of at least one eye or auxiliary apparatus (both infectious and non-infectious etiology: conjunctivitis, keratitis, uveitis, dacryocystitis etc.)
- Medical history of surgery on at least one eye during preceding 6 months.
- Medical history of heavy traumatic injury of eyes
- Patient has a cataract with high degree of lens opacification which can limit planned eye examination
- Patient prescribed for systemic corticosteroids or other medications treatment with proven effect leading on intraocular pressure increase
- Medical history or present dry eye syndrome accompanied by corneal and conjunctival xerosis
- Subcompensated or decompensated forms of chronic diseases of internal organs
- Clinically significant abnormalities in results of laboratory tests
- Any conditions limiting compliance (dementia, neuropsychiatric disease, drug and alcohol abuse etc.)
- Participation in other clinical trials (or administration of investigational drugs) during 3 months prior inclusion
- Patients with malignant tumors including postoperative period, patients receiving chemotherapy and/or radiotherapy.
- Patient's activated partial thromboplastin time exceeds normal levels more than 1,8 times
- Patients prescribed for anticoagulants treatment or patient received anticoagulants at least one hour prior lipoaspiration
- Medical history of heterotopic ossifications
- Patients prescribed for glycoprotein inhibitors treatment
- Acute vascular pathology
- Age-related macular degeneration
Exclusion Criteria:
- Patient's refusal from the further participation in trial
- Patient's refusal from compliance with the requirements of contraception during the participation in research
- Chronic kidney disease IV- V stages (creatinine clearance < 30 mL/min estimated by Cockroft-Gault formula)
- Confirmed syphilis, HIV, hepatitis B or C infections
Dropout Criteria:
- Direct indications on immediate initiation of treatment with medications with proven effect leading to intraocular pressure increase
- Pregnancy
- Development of cataract with high degree of lens opacification which can limit planned eye examination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: ADRC injection
Subjects will undergo liposuction under local anesthesia.
Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC).
After ADRC isolation autologous cells suspension will be injected into subtenon space of patient's eye.
|
ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SAEs and SARs monitoring
Time Frame: 4 weeks after treatment
|
Types, probability and severity of treatment emergent serious adverse events (SAEs) and serious adverse reactions (SARs)
|
4 weeks after treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in visual acuty
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Change from baseline in visual acuity assessed by visual acuty test
|
Follow up to completion (up to 48 weeks after treatment)
|
Changes in structures of fundus of the eye-1
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Changes in structures of fundus of the eye assessed by funduscopy: changes of configuration and size of optic disc, neuroretinal rim thinning, degree of optic disc pallor, hemorrhages on the optic nerve and retina, vascular changes, presence of degenerative changes of retina, optic disc drusen, edema and retinal detachment.
|
Follow up to completion (up to 48 weeks after treatment)
|
Changes in structures of fundus of the eye-2
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Changes in structures of fundus of the eye assessed by optical coherence tomography: changes of optic disc, neuroretinal rim and macula, retinal nerve fiber layer thickness.
|
Follow up to completion (up to 48 weeks after treatment)
|
Change in visual field
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Change from baseline in visual field assessed by computer perimetry
|
Follow up to completion (up to 48 weeks after treatment)
|
Change in retinal flicker responce
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Change from baseline in critical flicker fusion threshold
|
Follow up to completion (up to 48 weeks after treatment)
|
Change in intraocular pressure
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Change from baseline in intraocular pressure assessed by pneumotonometry and tonography
|
Follow up to completion (up to 48 weeks after treatment)
|
Quality of life monitoring
Time Frame: Follow up to completion (up to 48 weeks after treatment)
|
Quality of life estimated by validated questionnaires: the Short Form (36) Health Survey (SF-36)., Visual Functioning-14 Quality of Life (VF-14 QOL) and Glaucoma Quality of Life-15 (GQL-15)
|
Follow up to completion (up to 48 weeks after treatment)
|
Collaborators and Investigators
Investigators
- Study Director: Alina K Drakon, MD, Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation
- Principal Investigator: Ilya I Eremin, MD, PhD, Federal State Budgetary Institution "Central Clinical Hospital with Outpatient Health Center" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies
- Principal Investigator: Julia P Sotnikova, MD, Federal State Budgetary Institution "Outpatient Health Center №1" of the Business Administration for the President of the Russian Federation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- RU-CCH-02-01-14
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Degeneration
-
Seoul National University Bundang HospitalUnknownAge-Related Macular Degeneration | Retinal DrusenKorea, Republic of
-
University of LuebeckCompletedAge-Related Macular Degeneration | Retinal FunctionGermany
-
Guardion Health Sciences, Inc.Western University of Health Sciences; Eye Clinic of AustinCompletedMacular Degeneration | Age-related Macular Degeneration | Retinal DrusenUnited States
-
Stanford UniversityBascom Palmer Eye InstituteCompletedMacular Degeneration | Retinal DrusenUnited States
-
Medical University of GrazCompletedAge-Related Macular Degeneration | Retinal Blood VesselsAustria
-
Benha UniversityRecruitingMacula Lutea DegenerationUnited Arab Emirates
-
Sorlandet Hospital HFActive, not recruitingWet Macular DegenerationNorway
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationJapan
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationItaly
-
BayerRegeneron PharmaceuticalsCompletedWet Macular DegenerationFrance
Clinical Trials on Liposuction
-
AntriaCompletedSoft Tissue Mass RemovalUnited States
-
Assiut UniversityUnknown
-
University of AarhusCompletedMesenchymal Stem Cells
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Colorado...CompletedDisproportionate Shape | Expanded Fat PadsUnited States
-
Washington University School of MedicineCompletedDetermine Immune Cell Types in Subcutaneous Adipose TissueUnited States
-
Cairo UniversityUnknown
-
Sohag UniversityActive, not recruiting
-
Tampere University HospitalCompletedSubcutaneous Abdominal Fat | Abdominal Skin Elasticity | Rectus Muscle Diastasis | Unpleasant Body Contour
-
Shanghai Jiao Tong University School of MedicineCompletedMenstrual Irregularity
-
Haraldsplass Deaconess HospitalUniversity Hospital of North Norway; University of Bergen; St. Olavs Hospital; Sykehuset... and other collaboratorsRecruiting